Caseware UK (AP4) 2024.0.164 2024.0.164 2024-10-312024-10-31true2023-11-01false33trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 13709058 2023-11-01 2024-10-31 13709058 2024-10-31 13709058 2022-11-01 2023-10-31 13709058 2023-10-31 13709058 c:Director1 2023-11-01 2024-10-31 13709058 d:ComputerEquipment 2023-11-01 2024-10-31 13709058 d:ComputerEquipment 2024-10-31 13709058 d:ComputerEquipment 2023-10-31 13709058 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-11-01 2024-10-31 13709058 d:CurrentFinancialInstruments 2024-10-31 13709058 d:CurrentFinancialInstruments 2023-10-31 13709058 d:CurrentFinancialInstruments d:WithinOneYear 2024-10-31 13709058 d:CurrentFinancialInstruments d:WithinOneYear 2023-10-31 13709058 d:ShareCapital 2024-10-31 13709058 d:ShareCapital 2023-10-31 13709058 d:RetainedEarningsAccumulatedLosses 2024-10-31 13709058 d:RetainedEarningsAccumulatedLosses 2023-10-31 13709058 c:OrdinaryShareClass1 2023-11-01 2024-10-31 13709058 c:OrdinaryShareClass1 2024-10-31 13709058 c:OrdinaryShareClass1 2023-10-31 13709058 c:FRS102 2023-11-01 2024-10-31 13709058 c:AuditExempt-NoAccountantsReport 2023-11-01 2024-10-31 13709058 c:FullAccounts 2023-11-01 2024-10-31 13709058 c:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 13709058 e:PoundSterling 2023-11-01 2024-10-31 iso4217:GBP xbrli:shares xbrli:pure
Registered number: 13709058


GREENLEAF SURGICAL LIMITED








UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 OCTOBER 2024

 
GREENLEAF SURGICAL LIMITED
REGISTERED NUMBER: 13709058

BALANCE SHEET
AS AT 31 OCTOBER 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
638
-

  
638
-

Current assets
  

Debtors: amounts falling due within one year
 5 
1,312
1,196

Cash at bank and in hand
 6 
21
77

  
1,333
1,273

Creditors: amounts falling due within one year
 7 
(43,712)
(28,201)

Net current liabilities
  
 
 
(42,379)
 
 
(26,928)

Total assets less current liabilities
  
(41,741)
(26,928)

  

Net liabilities
  
(41,741)
(26,928)


Capital and reserves
  

Called up share capital 
 8 
100
100

Profit and loss account
  
(41,841)
(27,028)

  
(41,741)
(26,928)


Page 1

 
GREENLEAF SURGICAL LIMITED
REGISTERED NUMBER: 13709058
    
BALANCE SHEET (CONTINUED)
AS AT 31 OCTOBER 2024

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




S Patel
Director

Date: 31 October 2025

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
GREENLEAF SURGICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

1.


General information

Greenleaf Surgical Limited is a private company limited by shares, incorporated in the United Kingdom and registered in England and Wales. The principle place of business is 4 Bessemer Crescent, Rabans Lane Industrial Area, Aylesbury, Bucks, HP19 8TF.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements have been prepared on the going concern basis which assumes the
company will continue for the foreseeable future. The company have received commercial funding
during the year and are currently working on research and development projects which will result in
a claim for R&D tax credits. Given the nature of the business and the stage of completion of the
projects the going concern basis is deemed appropriate by the directors of the company.

 
2.3

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.4

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.
Grants of a revenue nature are recognised in the Statement of income and retained earnings in the same period as the related expenditure.

 
2.5

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

Page 3

 
GREENLEAF SURGICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

2.Accounting policies (continued)

 
2.6

Pensions

Defined contribution pension plan

The Company contributes to a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.7

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Computer equipment
-
25%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.8

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.10

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 4

 
GREENLEAF SURGICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

3.


Employees

The average monthly number of employees, including directors, during the year was 3 (2023 - 3).


4.


Tangible fixed assets





Computer equipment

£



Cost or valuation


Additions
666



At 31 October 2024

666



Depreciation


Charge for the year on owned assets
28



At 31 October 2024

28



Net book value



At 31 October 2024
638



At 31 October 2023
-


5.


Debtors

2024
2023
£
£


Other debtors
1,312
1,196

1,312
1,196



6.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
21
77

21
77


Page 5

 
GREENLEAF SURGICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2024

7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Other loans
2,500
-

Trade creditors
13,623
7,737

Amounts owed to associates
14,750
10,583

Other taxation and social security
1,180
3,619

Other creditors
10,159
4,762

Accruals and deferred income
1,500
1,500

43,712
28,201



8.


Share capital

2024
2023
£
£
Allotted, called up and partly paid



100 (2023 - 100) Ordinary shares of £1.00 each
100
100



9.


Pension commitments

The company contributes to a defined contribution pension scheme. The assets of the scheme are held
separately from those of the company in an independantly administered fund. The pension cost charge
represents contributions payable by the Company to the fund and amounted to £113.40 (2023 - £233.90).
Contributions totalling £48.60 (2023 - £100.24) were payable to the fund at the balance sheet date.


10.


Related party transactions

At the year end the company has an amount owing to Lynam Pharma Limited, a company of which Mr S Patel is a director of £5,949.70.


11.


Controlling party

The company was controlled throughout the year by S Patel by virtue of their shareholdings.

 
Page 6